PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis

Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced...

Full description

Saved in:
Bibliographic Details
Main Authors: Eun-Jin Go, Hannah Yang, Seung Joon Lee, Hyun Gul Yang, Jin A. Shin, Won Suk Lee, Hye Seong Lim, Hong Jae Chon, Chan Kim
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Angiogenesis
combination immunotherapy
immune checkpoint inhibitor
PB101
PlGF
tumor immunity
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2259212
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2259212

Similar Items